Current treatments of alzheimer disease: Are main caregivers satisfied with the drug treatments received by their patients?

Dementia and Geriatric Cognitive Disorders

Volumn 28, Issue 3, 2009, Pages 196-205

  Sevilla, C ^a   Jimenez Caballero P E ^b   Alfonso, V ^c   Gonzalez Adalid M ^d  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b HOSPITAL VIRGEN DE LA SALUD   (Spain)

^c European Biometrics Institute   (Spain)

^d PFIZER INC   (United States)

Author keywords

Alzheimer's disease treatment; Caregiver; Donepezil; Medical practice; SATMED Q; Treatment satisfaction

Indexed keywords

DONEPEZIL; GALANTAMINE; MEMANTINE; RIVASTIGMINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CAREGIVER SUPPORT; CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG EFFICACY; DRUG RELEASE; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; MONOTHERAPY; MULTICENTER STUDY; PATIENT SATISFACTION; PRIORITY JOURNAL; SCORING SYSTEM; STRUCTURED QUESTIONNAIRE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

AGED; ALZHEIMER DISEASE; CAREGIVERS; CHOLINESTERASE INHIBITORS; CROSS-SECTIONAL STUDIES; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; GALANTAMINE; HUMANS; INDANS; MALE; MEMANTINE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; NOOTROPIC AGENTS; PATIENT COMPLIANCE; PATIENT SATISFACTION; PHENYLCARBAMATES; PIPERIDINES; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMETRICS; QUESTIONNAIRES; SOCIOECONOMIC FACTORS; SPAIN;

EID: 69749089308     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000236015     Document Type: Article

References (59)

1. Daiello LA: Current issues in dementia pharmacotherapy. Am J Manag Care 2007; 13(suppl 8):S198-S202.
2. Burns A, O'Brien J, Auriacombe S, Ballard C, Broich K, Bullock R, Feldman H, Ford G, Knapp M, McCaddon A, Iliffe S, Jacova C, Jones R, Lennon S, McKeith I, Orgogozo JM, Purandare N, Richardson M, Ritchie C, Thomas A, Warner J, Wilcock G, Wilkinson D: Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology. J Psychopharmacol 2006; 20: 732-755.
3. Bartorelli L, Giraldi C, Saccardo M, Cammarata S, Bottini G, Fasanaro AM, Trequattrini A: Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease. Curr Med Res Opin 2005; 21: 1809-1818.
4. Schmidt R, Lechner A, Petrovic K: Rivastigmine in outpatient services: experience of 114 neurologists in Austria. Int Clin Psychopharmacol 2002; 17: 81-85.
5. Gonzalez-Gutierrez JL, Gobartt AL: Rivastigmine solution prescribing habits in patients with Alzheimer-type dementia in Spain (RIVASOL study) (in Spanish). Rev Neurol 2007; 44: 705-710.
6. Patterson CE, Passmore AP, Crawford VL: A 6-month open-label study of the effectiveness and tolerability of galantamine in patients with Alzheimer's disease. Int J Clin Pract 2004; 58: 144-148.
7. Brodaty H, Woodward M, Boundy K, Barnes N, Allen G: A naturalistic study of galantamine for Alzheimer's disease. CNS Drugs 2006; 20: 935-943.
8. Boada-Rovira M, Brodaty H, Cras P, Baloyannis S, Emre M, Zhang R, Bahra R: Efficacy and safety of donepezil in patients with Alzheimer's disease: results of a global, multinational, clinical experience study. Drugs Aging 2004; 21: 43-53.
9. Hager K, Calabrese P, Frolich L, Gobel C, Berger FM: An observational clinical study of the efficacy and tolerability of donepezil in the treatment of Alzheimer's disease. Dement Geriatr Cogn Disord 2003; 15: 189-198.
10. Cameron I, Curran S, Newton P, Petty D, Wattis J: Use of donepezil for the treatment of mild-moderate Alzheimer's disease: an audit of the assessment and treatment of patients in routine clinical practice. Int J Geriatr Psychiatry 2000; 15: 887-891.
11. Wallin AK, Andreasen N, Eriksson S, Batsman S, Nasman B, Ekdahl A, Kilander L, Grut M, Ryden M, Wallin A, Jonsson M, Olofsson H, Londos E, Wattmo C, Eriksdotter Jonhagen M, Minthon L: Donepezil in Alzheimer's disease: what to expect after 3 years of treatment in a routine clinical setting. Dement Geriatr Cogn Disord 2007; 23: 150-160.
12. Lopez-Pousa S, Robles A, Bermejo F, Masramon X, Rejas J, Leon T; Grupo Donaldffes: Resultados del estudio Donaldffes: cohorte de pacientes con EA leve a moderadamente grave tratados con donepezilo durante 2 años (in Spanish). Neurologia 2006; 21: 474-475.
13. Winblad B, Kilander L, Eriksson S, Minthon L, Batsman S, Wetterholm AL, Jansson-Blixt C, Haglund A: Donepezil in patients with severe Alzheimer's disease: double-blind, parallel- group, placebo-controlled study. Lancet 2006; 367: 1057-1065.
14. Black SE, Doody R, Li H, McRae T, Jambor KM, Xu Y, Sun Y, Perdomo CA, Richardson S: Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology 2007; 69: 459-469.
15. Doody RS: Refining treatment guidelines in Alzheimer's disease. Geriatrics 2005;(suppl): 14-20.
16. McShane R, Areosa Sastre A, Minakaran N: Memantine for dementia. Cochrane Database Syst Rev 2006:CD003154.
17. Winblad B, Jones RW, Wirth Y, Stoffler A, Mobius HJ: Memantine in moderate to severe Alzheimer's disease: a meta-analysis of randomised clinical trials. Dement Geriatr Cogn Disord 2007; 24: 20-27.
18. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I: Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. Jama 2004; 291: 317-324.
19. Hansen A, Gartlehner G, Webb A, Morgan LC, Moore CG, Jonas DE: Efficacy and safety of donepezil, galantamine and rivastigmine for the treatment of Alzheimer's disease, a systematic review and meta-analysis. Clin Interv Aging 2008; 3: 211-225.
20. Farlow R, Miller M, Pejovic V: Treatment options in Alzheimer's disease: maximizing benefit, managing expectations. Dement Geriatr Cogn Disord 2008; 25: 408-422.
21. Sicras-Mainar A, Vergara J, Leon-Colombo T, Febrer L, Rejas-Gutierrez J: Retrospective comparative analysis of antidementia medication persistence patterns in Spanish Alz heimer's disease patients treated with donepezil, rivastigmine, galantamine and memantine (in Spanish). Rev Neurol 2006; 43: 449-453.
22. Small G, Dubois B: A review of compliance to treatment in Alzheimer's disease: potential benefits of a transdermal patch. Curr Med Res Opin 2007; 23: 2705-2713.
23. Rogers SL, Doody RS, Pratt RD, Ieni JR: Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study. Eur Neuropsychopharmacol 2000; 10: 195-203.
24. McCarten JR, Rottunda SJ, Kuskowski MA: Change in the mini-mental state exam in Alzheimer's disease over 2 years: the experience of a dementia clinic. J Alzheimer's Dis 2004; 6: 11-15.
25. Winblad B, Wimo A, Engedal K, Soininen H, Verhey F, Waldemar G, Wetterholm AL, Haglund A, Zhang R, Schindler R: 3-year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy. Dement Geriatr Cogn Disord 2006; 21: 353-363.
26. Small GW, Kaufer D, Mendiondo MS, Quarg P, Spiegel R: Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years. Int J Clin Pract 2005; 59: 473-477. (Pubitemid 40467894)
27. Gillette-Guyonnet S, Andrieu S, Cortes F, Nourhashemi F, Cantet C, Ousset PJ, Reynish E, Grandjean H, Vellas B: Outcome of Alzheimer's disease: potential impact of cholinesterase inhibitors. J Gerontol A Biol Sci Med Sci 2006; 61: 516-520.
28. Becker M, Andel R, Rohrer L, Banks SM: The effect of cholinesterase inhibitors on risk of nursing home placement among Medicaid beneficiaries with dementia. Alzheimer Dis Assoc Disord 2006; 20: 147-152.
29. Zhou X, Xu J, Zhao Y: Risk factors of distress in Alzheimer's patients. Ann Acad Med Singapore 2007; 36: 253-258.
30. Howden CW: Management of acid-related disorders in patients with dysphagia. Am J Med 2004; 117(suppl 5A):44S-48S.
31. Eggenberger SK, Nelms TP: Artificial hydration and nutrition in advanced Alzheimer's disease: facilitating family decision-making. J Clin Nurs 2004; 13: 661-667.
32. Botella Trelis JJ, Ferrero Lopez MI: Nutrition of Alzheimer's patients in the family setting (in Spanish). Nutr Hosp 2004; 19: 154-159.
33. Wilkinson DG, Passmore AP, Bullock R, Hopker SW, Smith R, Potocnik FC, Maud CM, Engelbrecht I, Hock C, Ieni JR, Bahra RS: A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease. Int J Clin Pract 2002; 56: 441-446.
34. Wilcock G, Howe I, Coles H, Lilienfeld S, Truyen L, Zhu Y, Bullock R, Kershaw P: A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease. Drugs Aging 2003; 20: 777-789. (Pubitemid 36995254)
35. Jones RW, Soininen H, Hager K, Aarsland D, Passmore P, Murthy A, Zhang R, Bahra R: A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease. Int J Geriatr Psychiatry 2004; 19: 58-67.
36. Bullock R, Touchon J, Bergman H, Gambina G, He Y, Rapatz G, Nagel J, Lane R: Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. Curr Med Res Opin 2005; 21: 1317-1327.
37. Lopez-Pousa S, Turon-Estrada A, Garre- Olmo J, Pericot-Nierga I, Lozano-Gallego M, Vilalta-Franch M, Hernandez-Ferrandiz M, Morante-Munoz V, Isern-Vila A, Gelada- Batlle E, Majo-Llopart J: Differential efficacy of treatment with acetylcholinesterase inhibitors in patients with mild and moderate Alzheimer's disease over a 6-month period. Dement Geriatr Cogn Disord 2005; 19: 189-195.
38. Mossello E, Tonon E, Caleri V, Tilli S, Cantini C, Cavallini MC, Bencini F, Mecacci R, Marini M, Bardelli F, Sarcone E, Razzi E, Biagini CA, Masotti G: Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: a 'real world' study. Arch Gerontol Geriatr 2004; (suppl):297-307.
39. Aguglia E, Onor ML, Saina M, Maso E: An open-label, comparative study of rivastigmine, donepezil and galantamine in a realworld setting. Curr Med Res Opin 2004; 20: 1747-1752.
40. Caffarra P, Vezzadini G, Copelli S, Dieci F, Messa G, Nonis E, Venneri A: Comparing treatment effects in a clinical sample of patients with probable Alzheimer's disease treated with two different cholinesterase inhibitors. Acta Biomed 2007; 78: 16-21.
41. Atkinson MJ, Stewart WC, Fain JM, Stewart JA, Dhawan R, Mozaffari E, Lohs J: A new measure of patient satisfaction with ocular hypotensive medications: the Treatment Satisfaction Survey for Intraocular Pressure (TSS-IOP). Health Qual Life Outcomes 2003; 1: 67.
42. Acquadro C, Berzon R, Dubois D, Leidy NK, Marquis P, Revicki D, Rothman M: Incorporating the patient's perspective into drug development and communication: an ad hoc task force report of the Patient-Reported Outcomes (PRO) Harmonization Group meeting at the Food and Drug Administration, February 16, 2001. Value Health 2003; 6: 522-531.
43. Rothman ML, Beltran P, Cappelleri JC, Lipscomb J, Teschendorf B: Patient-reported outcomes: conceptual issues. Value Health 2007; 10(suppl 2):S66-S75.
44. Weaver M, Patrick DL, Markson LE, Martin D, Frederic I, Berger M: Issues in the measurement of satisfaction with treatment. Am J Manag Care 1997; 3: 579-594.
45. Nett RB, Tiseo PJ, Almas M, Sikes CR: Patient satisfaction with eletriptan in the acute treatment of migraine in primary care. Int J Clin Pract 2007; 61: 1677-1685.
46. Shikiar R, Rentz AM: Satisfaction with medication: an overview of conceptual, methodologic, and regulatory issues. Value Health 2004; 7: 204-215.
47. Mucha L, Shaohung S, Cuffel B, McRae T, Mark TL, Del Valle M: Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer's disease. J Manag Care Pharm 2008; 14: 451-461.
48. Sicras A, Rejas-Gutierrez J: Drug-cholinesterase- inhibitors persistence patterns in treated patients with dementia of Alzheimer type: retrospective comparative analysis of donepezil, rivastigmine and galantamine (in Spanish). Rev Neurol 2004; 39: 312-316.
49. Ruiz MA, Pardo A, Rejas J, Soto J, Villasante F, Aranguren JL: Development and validation of the 'Treatment Satisfaction with Medicines Questionnaire' (SATMED-Q). Value Health 2008; 11: 913-925.
50. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. J Postgrad Med 2002; 48: 206-208.
51. Diagnostic and Statistical Manual of Mental Disorders (DSM IV), ed 4. Washington, American Psychiatric Association, 1994.
52. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-944.
53. Folstein MF, Folstein SE, McHugh PR: 'Minimental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
54. Blesa R, Pujol M, Aguilar M, Santacruz P, Bertran-Serra I, Hernandez G, Sol JM, Pena- Casanova J: Clinical validity of the 'mini-mental state' for Spanish speaking communities. Neuropsychologia 2001; 39: 1150-1157.
55. National Institute for Health and Clinical Excellence: donepezil, galantamine, riva s tigmine (review) and memantine for the treatment of Alzheimer's disease (amended). London, National Institute for Health and Clinical Excellence, 2007.
56. Jones RW, Bayer A, Inglis F, Barker A, Phul R: Safety and tolerability of once-daily versus twice-daily memantine: a randomised, double-blind study in moderate to severe Alzheimer's disease. Int J Geriatr Psychiatry 2007; 22: 258-262.
57. Blesa R, Ballard C, Orgogozo JM, Lane R, Thomas SK: Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer disease. Neurology 2007; 69:S23-S28. (Pubitemid 47205656)
58. Suárez-Fernández C, Ruiz MA, Sanz de Burgoa V, Martínez Castelao A, Luque M: Evaluación del cumplimiento terapéutico en hipertensos atendidos en unidades de HTA y su relación con el control de la HTA (in Spanish). Hipertensión 2007; 24(suppl 2):77.
59. Sancho J, Pena P, Rufo M, Palacios G, Masramon X, Rejas J: Health and non-health care resources use in the management of adult outpatients with drug-resistant epilepsy in Spain: a cost-of-illness study (LINCE study). Epilepsy Res 2008; 81: 176-187.